论文部分内容阅读
目的探究替罗非班应用于急性ST段抬高心肌梗死介入治疗的临床效果。方法 114例急性ST段抬高心肌梗死患者,按照计算机数字法分为对照组和治疗组,各57例。所有入选患者均给予急诊冠状动脉介入治疗,对照组患者术前未予以盐酸替罗非班,治疗组患者术前予以盐酸替罗非班,比较两组术后不良事件发生率及冠状动脉血流情况。结果治疗组TIMI 0级0例,TIMI 1级3例(5.26%),TIMI 2级15例(26.32%),TIMI 3级39例(68.42%),对照组TIMI 0级0例,TIMI 1级5例(8.77%),TIMI 2级27例(47.37%),TIMI 3级25例(43.85%);治疗组TIMI2级例数明显低于对照组,TIMI 3级例数明显高于对照组,差异具有统计学意义(P<0.05)。治疗组术后不良事件发生率为7.02%,对照组为26.32%,比较差异具有统计学意义(P<0.05)。结论急性ST段抬高心肌梗死介入治疗术前予以盐酸替罗非班,可显著提高治疗效果,防止不良事件的发生,值得临床使用和全面推广。
Objective To investigate the clinical effect of tirofiban in the interventional treatment of acute ST-segment elevation myocardial infarction. Methods A total of 114 patients with acute ST-elevation myocardial infarction were divided into control group and treatment group according to the computer numerical method, with 57 cases in each. All patients were enrolled in emergency PCI. Patients in the control group were treated with tirofiban hydrochloride before operation. Patients in the treatment group were given tirofiban hydrochloride preoperatively. The incidence of postoperative adverse events and coronary blood flow Happening. Results There were 0 TIMI 0, 3 TIMI 1 (5.26%), 15 TIMI 2 (26.32%), 39 TIMI 3 (68.42%) and 0 TIMI 0 5 cases (8.77%), TIMI 2 grade 27 cases (47.37%) and TIMI 3 grade 25 cases (43.85%). The TIMI 2 level in the treatment group was significantly lower than that in the control group, TIMI 3 level was significantly higher than the control group, The difference was statistically significant (P <0.05). The incidence of postoperative adverse events was 7.02% in the treatment group and 26.32% in the control group, with statistical significance (P <0.05). Conclusion Tirofiban hydrochloride can be used before interventional treatment of acute ST-segment elevation myocardial infarction, which can significantly improve the therapeutic effect and prevent the occurrence of adverse events. It is worth clinical application and promotion.